Increased S100B serum levels have been considered as a marker of glial pathology, brain
damage, and blood–brain-barrier impairment. However, S100B expression has also been …

S100B protein is mainly synthesized in glial cells and modulates the balance between cell
proliferation and differentiation in neurons and glial cells. However, S100B is not CNS …

Elevated blood levels of S100B in neuropsychiatric disorders have so far been mainly
attributed to glial pathologies. However, increases or dysfunction of adipose tissue may be …

S100B, established as prevalent protein of the central nervous system, is a peripheral
biomarker for blood-brain barrier disruption and often also a marker of brain injury. However …

Objective: Previous studies have provided robust evidence that cognitive impairment exists
in patients with type 2 diabetes. The predictive role of S100B in a variety of …

Glucose metabolism in neuronal tissue declines during neurodegenerative disorders in a
progressive, region-specific, and disease-specific manner. Studies have shown that …

BACKGROUND: S100B is a calcium-binding protein expressed and secreted by astrocytes;
serum and cerebrospinal fluid (CSF) S100B elevation has been proposed as an index of …

The S100B protein is abundant in the nervous system, mainly in astrocytes, and is also
present in other districts. Among these, the adipose tissue is a site of concentration for the …

Adipocytes contain high levels of S100B and in vitro assays indicate a modulated secretion
of this protein by hormones that regulate lipolysis, such as glucagon, adrenaline, and …

S100B (member of a family of proteins that are 100% soluble in ammonium sulfate at neutral
pH) has been widely used as astrocyte marker in animal models and in human brain …